Innoviva, Inc. (INVA) vs Kailera Therapeutics, Inc. (KLRA)

A side-by-side comparison of Innoviva, Inc. and Kailera Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Innoviva, Inc. logo
INVA
Innoviva, Inc.
$1.54B
$20.87HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT
Kailera Therapeutics, Inc. logo
KLRA
Kailera Therapeutics, Inc.
$1.42B
$10.95HealthcareDelayed quote: Oct 6, 2026, 11:05 AM EDT

Total return — INVA vs KLRA

growth of $100 · dividends reinvested · last 1y
INVA -13.1% (-13.1%/yr)KLRA -58.3% (-58.3%/yr)INVA compounded faster over this window
406080100Start $100$87$42
INVA KLRA

INVA vs KLRA: by the numbers

  • •INVA is the larger company ($1.54B vs $1.42B market cap).
  • •INVA is profitable (80.56% net margin) while KLRA runs a net loss (0.00%).

Metrics side by side

Valuation

MetricINVAKLRA
P/E ratio5.09N/A
Forward P/E8.62N/A
PEG ratio0.49N/A
P/S ratio3.47N/A
P/B ratio1.251.27
EV / EBITDA4.91N/A
FCF yield12.23%N/A

Profitability

MetricINVAKLRA
Gross margin73.09%0.00%
Operating margin36.66%0.00%
Net margin80.56%0.00%
ROE28.97%N/A
ROIC8.36%-24.52%

Growth (annualized)

MetricINVAKLRA
Revenue CAGR (5Y)3.94%N/A
EPS CAGR (5Y)12.71%N/A
FCF CAGR (5Y)-10.54%N/A
Total return CAGR (5Y)4.52%N/A

Frequently asked

Is INVA or KLRA more profitable?
INVA runs the higher net margin — INVA at 80.56% versus KLRA at 0.00%.

Go deeper

Full INVA analysisFull KLRA analysisInteractive comparison tool

Dig into the metrics

Innoviva P/E ratioInnoviva ROEKailera Therapeutics ROEInnoviva operating marginKailera Therapeutics operating marginInnoviva revenue growthKailera Therapeutics revenue growthInnoviva free cash flowKailera Therapeutics free cash flow

Innoviva & Kailera Therapeutics appear in these rankings

Highest ROE StocksHighest Operating Margin StocksHighest FCF Yield StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.